Chemotherapy-Induced Myelosuppression in Esophageal Cancer Patients: Risks and Suggestions for Its Management

Abstract

Objective

The influential factors of chemotherapy-induced myelosuppression in esophageal cancer in central China are unclear. This study aimed to investigate the effect of commonly used chemotherapy regimens on the incidence of myelosuppression in clinical treatment of esophageal cancer.

Methods

In this retrospective study, 624 patients with esophageal cancer who received six different chemotherapy regimens between 2013 and 2020 at our institute were included. Chemotherapy consisted of lobaplatin, 5-fluorouracil (5-F), lobaplatin and 5-F, nedaplatin, nedaplatin and paclitaxel (PTX), cisplatin and PTX. Multivariable logistic regression analysis was used to explore the risk of myelosuppression among the six different chemotherapy regimens.

Results

Compared with lobaplatin group, the incidence of myelosuppression in patients treated with chemotherapy regimens of lobaplatin and 5-F, nedaplatin, nedaplatin and PTX and cisplatin and PTX were significantly ameliorated. The dose of lobaplatin was significantly reduced (P=0.007) when lobaplatin was combined with 5-F, and the combination could significantly reduce the risk of myelosuppression (P=0.022). Furthermore, chemotherapeutic regimens, the dose of platinum, hemoglobin and uric acid levels, age, sex, total bilirubin and immune-enhancing drugs were found to be strong predictors of developing myelosuppression.

Conclusion

Targeted preventive interventions that enhance immune function, reduce uric acid levels and choose combined medication during chemotherapy should be implemented for high-risk patients to reduce the occurrence of myelosuppression. In addition, the dose of lobaplatin should be adjusted when combined with other chemotherapy drugs to reduce the incidence of myelosuppression.

Keywords

esophageal cancer / myelosuppression / chemotherapy

References

[1] AllemaniC, MatsudaT, Di CarloV, et al.. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (London, England), 2018, 391(10125): 1023-1075

[2] BollschweilerE, PlumP, MonigSP, et al.. Current and future treatment options for esophageal cancer in the elderly. Expert Opin Pharmacother, 2017, 18(10): 1001-1010

[3] PickensA, OrringerMB. Geographical distribution and racial disparity in esophageal cancer. Ann Thorac Surg, 2003, 76(4): S1367-1369

[4] BosettiC, LeviF, FerlayJ, et al.. Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer, 2008, 122(5): 1118-1129

[5] LordickF, MarietteC, HaustermansK, et al.. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann oncol, 2016, 27(suppl5): v50-v57

[6] AjaniJA, J.S. BarthelJS, BentremDJ, et al.. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw, 2011, 9(8): 830-887

[7] WatanabeM, OtakeR, KozukiR, et al.. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today, 2020, 50(1): 12-20

[8] Fatehi HassanabadA, ChehadeR, BreadnerD, et al.. Esophageal carcinoma: Towards targeted therapies. Cell Oncol (Dordr), 2020, 43(2): 195-209

[9] CarrC, NgJ, WigmoreT. The side effects of chemotherapeutic agents. Curr Anaesth Crit Care, 2008, 19(2): 70-79

[10] CrawfordJ, DaleDC, LymanGH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer, 2004, 100(2): 228-237

[11] GroopmanJE, ItriLM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst, 1999, 91(19): 1616-1634

[12] KuterDJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology, 2015, 29(4): 282-294

[13] BarretoJN, McCulloughKB, IceLL, et al.. Antineoplastic agents and the associated myelosuppressive effects: a review. J Pharm Pract, 2014, 27(5): 440-446

[14] TaylorSJ, DuyvestynJM, DaggerSA, et al.. Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. Sci Transl Med, 2017, 9(402): eaa-8060

[15] YinWJ, YiYH, GuanXF, et al.. Preprocedural Prediction Model for Contrast-Induced Nephropathy Patients. J Am Heart Assoc, 2017, 6(2): e004498

[16] EpsteinRS, AaproMS, Basu RoyUK, et al.. Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors. Adv Ther, 2020, 37(8): 3606-3618

[17] Grading standard for acute and subacute toxicity of anticancer drugs (WHO standard), Cancer, 1992,(3):254

[18] SaggamA, KaleP, ShenguleS, et al.. Ayurveda-based Botanicals as Therapeutic Adjuvants in Paclitaxel-induced Myelosuppression. Front Pharmacol, 2022, 13: 835616

[19] ZhengY, LiY, LiuX, et al.. Multicentre Comparison of the Toxicity and Effectiveness of Lobaplatin-Based Versus Cisplatin-Based Adjuvant Chemotherapy in Oesophageal Carcinoma. Front Oncol, 2021, 11: 668140

[20] ParkMH, JungIK, MinWK, et al.. Neuropeptide Y improves cisplatin-induced bone marrow dysfunction without blocking chemotherapeutic efficacy in a cancer mouse model. BMB reports, 2017, 50(8): 417-422

[21] JavarappaKK, D. TsallosD, HeckmanCA. A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. SLAS Discov, 2018, 23(7): 687-696

[22] ReddelCJ, TanCW, ChenVM. Thrombin Generation and Cancer: Contributors and Consequences. Cancers, 2019, 11(1): 100

[23] SunW, RenH, GaoCT, et al.. Clinical and Prognostic Significance of Coagulation Assays in Pancreatic Cancer Patients With Absence of Venous Thromboembolism. American J Clin Oncol, 2015, 38(6): 550-556

[24] BestariMB, AgustantiN. Obstructive jaundice due to pancreatic metastasis from non-small cell lung cancer. Acta medica Indonesiana, 2013, 45(3): 216-219

[25] WangXB, WuDJ, ChenWP, et al.. Impact of radiotherapy on immunological parameters, levels of inflammatory factors, and clinical prognosis in patients with esophageal cancer. J Radiat Res, 2019, 60(3): 353-363

[26] BhatS, ColemanHG, YousefF, et al.. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst, 2011, 103(13): 1049-1057

[27] HuangFL, YuSJ. Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg, 2018, 41(3): 210-215

[28] CookMB, ChowWH, DevesaSS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977–2005. Brit J Cancer, 2009, 101(5): 855-859

[29] OhiraM, KuboN, YamashitaY, et al.. Impact of Chemoradiation-induced Myelosuppression on Prognosis of Patients with Locally Advanced Esophageal Cancer After Chemoradiotherapy Followed by Esophagectomy. Anticancer Res, 2015, 35(9): 4889-4895

[30] OjimaT, NakamoriM, NakamuraM, et al.. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus. Dis Esophagus, 2017, 30(2): 1-7

[31] LanYQ, WuRP, HuangXB, et al.. Paclitaxel, oxaliplatin, 5-fluorouracil and leucovorin combination chemotherapy in patients with recurrent or metastatic gastric cancer. Tumori, 2018, 104(1): 22-29

[32] LiuJ, WangZ, WuK, et al.. Paclitaxel or 5-fluorouracil/esophageal stent combinations as a novel approach for the treatment of esophageal cancer. Biomaterials, 2015, 53: 592-599